Cargando…
Salmon Protein Hydrolysate Potentiates the Growth Inhibitory Effect of Bicalutamide on Human Prostate Cancer Cell Lines LNCaP and PC3 by Modulating Iron Homeostasis
Prostate cancer is a common cause of cancer death in men. In advanced stages of prostate cancer, androgen deprivation therapy (ADT) is initiated. Despite ADT, prostate cancers invariably progress to become androgen independent. A growing body of evidence implicates iron dysmetabolism in prostate can...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032914/ https://www.ncbi.nlm.nih.gov/pubmed/35447901 http://dx.doi.org/10.3390/md20040228 |
_version_ | 1784692762257391616 |
---|---|
author | Bjerknes, Christian Framroze, Bomi Currie, Crawford Pettersen, Caroline Hild Hakvåg Axcrona, Karol Hermansen, Erland |
author_facet | Bjerknes, Christian Framroze, Bomi Currie, Crawford Pettersen, Caroline Hild Hakvåg Axcrona, Karol Hermansen, Erland |
author_sort | Bjerknes, Christian |
collection | PubMed |
description | Prostate cancer is a common cause of cancer death in men. In advanced stages of prostate cancer, androgen deprivation therapy (ADT) is initiated. Despite ADT, prostate cancers invariably progress to become androgen independent. A growing body of evidence implicates iron dysmetabolism in prostate cancer progression. A bioactive peptide-rich salmon protein hydrolysate (SPH) has previously been demonstrated to modulate iron homeostatic mechanisms. In the present study, the anticancer effect of SPH and bicalutamide co-treatment on LNCaP and PC3 prostate cancer cell proliferation was investigated. Our results found that SPH potentiates the anti-proliferative effect of bicalutamide in a dose-dependent manner for both cell lines. In the presence of 160 µg/mL SPH, co-treatment with 1.0 µM bicalutamide decreased LNCaP cells’ relative colony survival from 25% (1.0 µM bicalutamide monotreatment) to 2% after culturing for 12 days. For PC3 cells, the relative colony survival diminished from 52% (10.0 µM bicalutamide) to 32% at an SPH concentration of 160 µg/mL. Gene expression profiling, employing quantitative real-time PCR, revealed that the inhibitory effects were related to significant FTH1 up-regulation with a concomitant TFRC down-regulation. In conclusion, our results provide in vitro evidence that SPH potentiates the growth inhibitory effect of bicalutamide on prostate cancer cells by modulating iron homeostasis mechanisms. |
format | Online Article Text |
id | pubmed-9032914 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90329142022-04-23 Salmon Protein Hydrolysate Potentiates the Growth Inhibitory Effect of Bicalutamide on Human Prostate Cancer Cell Lines LNCaP and PC3 by Modulating Iron Homeostasis Bjerknes, Christian Framroze, Bomi Currie, Crawford Pettersen, Caroline Hild Hakvåg Axcrona, Karol Hermansen, Erland Mar Drugs Article Prostate cancer is a common cause of cancer death in men. In advanced stages of prostate cancer, androgen deprivation therapy (ADT) is initiated. Despite ADT, prostate cancers invariably progress to become androgen independent. A growing body of evidence implicates iron dysmetabolism in prostate cancer progression. A bioactive peptide-rich salmon protein hydrolysate (SPH) has previously been demonstrated to modulate iron homeostatic mechanisms. In the present study, the anticancer effect of SPH and bicalutamide co-treatment on LNCaP and PC3 prostate cancer cell proliferation was investigated. Our results found that SPH potentiates the anti-proliferative effect of bicalutamide in a dose-dependent manner for both cell lines. In the presence of 160 µg/mL SPH, co-treatment with 1.0 µM bicalutamide decreased LNCaP cells’ relative colony survival from 25% (1.0 µM bicalutamide monotreatment) to 2% after culturing for 12 days. For PC3 cells, the relative colony survival diminished from 52% (10.0 µM bicalutamide) to 32% at an SPH concentration of 160 µg/mL. Gene expression profiling, employing quantitative real-time PCR, revealed that the inhibitory effects were related to significant FTH1 up-regulation with a concomitant TFRC down-regulation. In conclusion, our results provide in vitro evidence that SPH potentiates the growth inhibitory effect of bicalutamide on prostate cancer cells by modulating iron homeostasis mechanisms. MDPI 2022-03-28 /pmc/articles/PMC9032914/ /pubmed/35447901 http://dx.doi.org/10.3390/md20040228 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bjerknes, Christian Framroze, Bomi Currie, Crawford Pettersen, Caroline Hild Hakvåg Axcrona, Karol Hermansen, Erland Salmon Protein Hydrolysate Potentiates the Growth Inhibitory Effect of Bicalutamide on Human Prostate Cancer Cell Lines LNCaP and PC3 by Modulating Iron Homeostasis |
title | Salmon Protein Hydrolysate Potentiates the Growth Inhibitory Effect of Bicalutamide on Human Prostate Cancer Cell Lines LNCaP and PC3 by Modulating Iron Homeostasis |
title_full | Salmon Protein Hydrolysate Potentiates the Growth Inhibitory Effect of Bicalutamide on Human Prostate Cancer Cell Lines LNCaP and PC3 by Modulating Iron Homeostasis |
title_fullStr | Salmon Protein Hydrolysate Potentiates the Growth Inhibitory Effect of Bicalutamide on Human Prostate Cancer Cell Lines LNCaP and PC3 by Modulating Iron Homeostasis |
title_full_unstemmed | Salmon Protein Hydrolysate Potentiates the Growth Inhibitory Effect of Bicalutamide on Human Prostate Cancer Cell Lines LNCaP and PC3 by Modulating Iron Homeostasis |
title_short | Salmon Protein Hydrolysate Potentiates the Growth Inhibitory Effect of Bicalutamide on Human Prostate Cancer Cell Lines LNCaP and PC3 by Modulating Iron Homeostasis |
title_sort | salmon protein hydrolysate potentiates the growth inhibitory effect of bicalutamide on human prostate cancer cell lines lncap and pc3 by modulating iron homeostasis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032914/ https://www.ncbi.nlm.nih.gov/pubmed/35447901 http://dx.doi.org/10.3390/md20040228 |
work_keys_str_mv | AT bjerkneschristian salmonproteinhydrolysatepotentiatesthegrowthinhibitoryeffectofbicalutamideonhumanprostatecancercelllineslncapandpc3bymodulatingironhomeostasis AT framrozebomi salmonproteinhydrolysatepotentiatesthegrowthinhibitoryeffectofbicalutamideonhumanprostatecancercelllineslncapandpc3bymodulatingironhomeostasis AT curriecrawford salmonproteinhydrolysatepotentiatesthegrowthinhibitoryeffectofbicalutamideonhumanprostatecancercelllineslncapandpc3bymodulatingironhomeostasis AT pettersencarolinehildhakvag salmonproteinhydrolysatepotentiatesthegrowthinhibitoryeffectofbicalutamideonhumanprostatecancercelllineslncapandpc3bymodulatingironhomeostasis AT axcronakarol salmonproteinhydrolysatepotentiatesthegrowthinhibitoryeffectofbicalutamideonhumanprostatecancercelllineslncapandpc3bymodulatingironhomeostasis AT hermansenerland salmonproteinhydrolysatepotentiatesthegrowthinhibitoryeffectofbicalutamideonhumanprostatecancercelllineslncapandpc3bymodulatingironhomeostasis |